GO44145: A phase 3 trial of glofitamab and Pola-R-CHP in people with B-cell lymphoma

This trial is testing the medication glofitamab when given in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (Pola-R-CHP) in people with untreated CD20-positive large B-cell lymphoma. 

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT06047080
 

Trial aim and background  

The aim of this trial is to see how effective the medication glofitamab is when given with Pola-R-CHP in people with large B-cell lymphoma which has not previously been treated. It will be compared against Pola-R-CHP on its own.

Glofitamab is a type of targeted treatment called a bispecfic antibody. This means it sticks to two different target proteins, one on the lymphoma cells, and one on healthy T cells. This helps the T cells to find the lymphoma cells and destroy them.

Who can enter 

People with untreated CD20-positive large B-cell lymphoma may be eligible for this trial.

Locations 

Recruitment is taking place in the following UK locations:

  • Blackpool Victoria Hospital, Blackpool
  • East Kent Hospitals University NHS Foundation Trust
  • Royal Devon and Exeter Hospital, Exeter
  • Beatson West of Scotland Cancer Centre, Glasgow
  • Leeds Teaching Hospital NHS Trust, Leeds
  • University College London Hospitals NHS Foundation Trust, London
  • Guy’s Hospital, London
  • Newcastle University, Newcastle
  • Nottingham University Hospitals NHS Trust, Nottingham
  • Churchill Hospital, Oxford

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT06047080

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.